These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6424275)

  • 1. Pharmacokinetics of enteric-coated valproic acid.
    Albright PS; Bruni J; Suria D
    Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
    Hoffmann F; Jancik BC; von Unruh GE
    Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
    Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
    Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
    Johannessen SI; Henriksen O
    Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of valproic acid under fasting/nonfasting regimens.
    Chun AH; Hoffman DJ; Friedmann N; Carrigan PJ
    J Clin Pharmacol; 1980 Jan; 20(1):30-6. PubMed ID: 6766956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
    Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
    Anderson P; Elwin CE
    Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic comparison of two valproic acid formulations--a plain and a controlled release enteric-coated tablets.
    Rha JH; Jang IJ; Lee KH; Chong WS; Shin SG; Lee N; Myung HJ
    J Korean Med Sci; 1993 Aug; 8(4):251-6. PubMed ID: 8198761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.
    Schapel GJ; Beran RG; Doecke CJ; O'Reilly WJ; Reece PA; Rischbieth RH; Sansom LN; Stanley PE
    Eur J Clin Pharmacol; 1980 Jan; 17(1):71-7. PubMed ID: 6768573
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacokinetic study of sodium di-n-propylacetate (usual tablet and enteric coated tablet with delayed absorption) (author's transl)].
    van de Mortel I; franck G
    Acta Neurol Belg; 1976; 76(3):165-72. PubMed ID: 788439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 15. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On the enteral absorption of valproic acid (author's transl)].
    Oelkers W; Stoffels G; Schäfer H; Reith H
    Arzneimittelforschung; 1977; 27(5):1088-90. PubMed ID: 328020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the serum concentration profile of enteric-coated valproic acid.
    Fischer JH; Barr AN; Paloucek FP; Dorociak JV; Spunt AL
    Neurology; 1988 Aug; 38(8):1319-22. PubMed ID: 3135514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.